S. Rittenhouse

发表

Challenges of antibacterial discovery revisited

David J Payne, Michael N Gwynn, D. Payne, 2010, Annals of the New York Academy of Sciences.

Discovery of a Novel and Potent Class of FabI-Directed Antibacterial Agents

Martha S. Head, Xiayang Qiu, Cheryl A. Janson, 2002, Antimicrobial Agents and Chemotherapy.

Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK.

Xiayang Qiu, David J Payne, M. Head, 2003, Journal of medicinal chemistry.

Optimisation of aryl substitution leading to potent methionyl tRNA synthetase inhibitors with excellent gram-positive antibacterial activity.

A. K. Forrest, R. Sheppard, Murray J. B. Brown, 2003, Bioorganic & medicinal chemistry letters.

Evaluation of 500 gram negative isolates to determine the number of major susceptibility interpretation discrepancies between the Vitek and MicroScan Walkaway for 9 antimicrobial agents.

L. Miller, J. Poupard, S. Rittenhouse, 1996, Diagnostic microbiology and infectious disease.

Variable Sensitivity to Bacterial Methionyl-tRNA Synthetase Inhibitors Reveals Subpopulations of Streptococcus pneumoniae with Two Distinct Methionyl-tRNA Synthetase Genes

James R. Brown, M. Stanhope, D. Holmes, 2003, Antimicrobial Agents and Chemotherapy.

Comparison of mupirocin susceptibility of nasal and nonnasal Staphylococcus aureus isolates.

J. Poupard, S. Rittenhouse, L. J. Utrup, 1994, Diagnostic microbiology and infectious disease.

Novel tricyclics (e.g., GSK945237) as potent inhibitors of bacterial type IIA topoisomerases.

S. Dabbs, D. Davies, E. Minthorn, 2016, Bioorganic & medicinal chemistry letters.

Novel hydroxyl tricyclics (e.g., GSK966587) as potent inhibitors of bacterial type IIA topoisomerases.

S. Dabbs, D. Davies, E. Minthorn, 2013, Bioorganic & medicinal chemistry letters.

Novel cyclohexyl-amides as potent antibacterials targeting bacterial type IIA topoisomerases.

S. Dabbs, D. Davies, Susanne Eyrisch, 2011, Bioorganic & medicinal chemistry letters.

Novel amino-piperidines as potent antibacterials targeting bacterial type IIA topoisomerases.

S. Dabbs, D. Davies, T. Gallagher, 2011, Bioorganic & medicinal chemistry letters.

A rapid microtiter plate assay for measuring the effect of compounds on Staphylococcus aureus membrane potential.

M. Gwynn, John Johnson, D. Gentry, 2010, Journal of microbiological methods.

Structure and antimicrobial activity of new bile acid-based gemini surfactants

P. Camilleri, G. Woodnutt, S. Rittenhouse, 2002 .

Inhibitors of bacterial enoyl acyl carrier protein reductase (FabI): 2,9-disubstituted 1,2,3,4-tetrahydropyrido[3,4-b]indoles as potential antibacterial agents.

C. Janson, A. Fosberry, D. D. Jaworski, 2001, Bioorganic & medicinal chemistry letters.

Definition of the heterocyclic pharmacophore of bacterial methionyl tRNA synthetase inhibitors: potent antibacterially active non-quinolone analogues.

A. K. Forrest, Murray J. B. Brown, R. Copley, 2004, Bioorganic & medicinal chemistry letters.

Identification of a Series of Tricyclic Natural Products as Potent Broad-Spectrum Inhibitors of Metallo-β-Lactamases

Cheryl A. Janson, C. Janson, D. Tew, 2002, Antimicrobial Agents and Chemotherapy.

Synthesis and activity of analogues of SB-219383: novel potent inhibitors of bacterial tyrosyl tRNA synthetase.

A. Pope, S. Rittenhouse, L. Mensah, 2000, The Journal of antibiotics.

Defining and Combating the Mechanisms of Triclosan Resistance in Clinical Isolates of Staphylococcus aureus

M. Head, N. Wallis, D. Payne, 2002, Antimicrobial Agents and Chemotherapy.

1,4-Disubstituted imidazoles are potential antibacterial agents functioning as inhibitors of enoyl acyl carrier protein reductase (FabI).

C. Janson, A. Fosberry, Ward W. Smith, 2001, Bioorganic & medicinal chemistry letters.

Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI).

Xiayang Qiu, David J Payne, M. Head, 2002, Journal of medicinal chemistry.

New benzylidenethiazolidinediones as antibacterial agents.

D. Heerding, D. Holmes, S. Rittenhouse, 2003, Bioorganic & medicinal chemistry letters.

A survey of beta-lactamase-producing Haemophilus influenzae. An evaluation of 5750 isolates.

R. L. Kaplan, L. Miller, J. Poupard, 1995, Diagnostic microbiology and infectious disease.

Nanomolar inhibitors of Staphylococcus aureus methionyl tRNA synthetase with potent antibacterial activity against gram-positive pathogens.

A. K. Forrest, H. Boyd, R. Sheppard, 2002, Journal of medicinal chemistry.

New benzylidenethiazolidinediones as antibacterial agents.

D. Heerding, D. Holmes, S. Rittenhouse, 2003, Bioorganic & medicinal chemistry letters.

The evolution of antimicrobial susceptibility testing methods.

J. Poupard, S. Rittenhouse, L. R. Walsh, 1994, Advances in experimental medicine and biology.

Susceptibilities of 123 strains of Xanthomonas maltophilia to eight beta-lactams (including beta-lactam-beta-lactamase inhibitor combinations) and ciprofloxacin tested by five methods

M. Jacobs, P. Appelbaum, G. Pankuch, 1994, Antimicrobial Agents and Chemotherapy.

Stepwise Exposure of Staphylococcus aureus to Pleuromutilins Is Associated with Stepwise Acquisition of Mutations in rplC and Minimally Affects Susceptibility to Retapamulin

D. Holmes, D. Gentry, S. Rittenhouse, 2007, Antimicrobial Agents and Chemotherapy.

Genetic Characterization of Vga ABC Proteins Conferring Reduced Susceptibility to Pleuromutilins in Staphylococcus aureus

M. Gwynn, D. Holmes, D. Gentry, 2008, Antimicrobial Agents and Chemotherapy.

Conformational restriction of methionyl tRNA synthetase inhibitors leading to analogues with potent inhibition and excellent gram-positive antibacterial activity.

A. Pope, S. Rittenhouse, P. Brown, 2003, Bioorganic & medicinal chemistry letters.